评估I型子宫内膜癌的ETV5和RUNX1表达及其与子宫肌层浸润的相关性

ASSESSMENT OF ETV5 AND RUNX1 EXPRESSION IN TYPE I ENDOMETRIAL CARCINOMA AND ITS ASSOCIATION WITH MYOMETRIAL INVASION

Introduction: Endometrioid adenocarcinoma is the most common type of endometrial cancer: 80 to 90% of cases. Most of them are diagnosed in early stages and have a favorable prognosis, but some may present an unexpected recurrence, resistant to treatment. Prognosis is based solely on clinicopathological features, such as myometrial invasion. ETV5/ERM and RUNX1/AML1 expression present marked altered expression in stage IB endometrioid tumors. Therefore the purpose of this study was to evaluate the relation between ETV5/ERM and RUNX1/AML1 protein expression and myometrial invasion.
Material and methods: 169 patients with endometrioid adenocarcinoma underwent surgery at the Brazilian National Cancer Institute from 2007 to 2009. ETV5/ERM and RUNX1/AML1 protein expression was analyzed through immunohistochemistry (IHC) and evaluated as the percentage of IHC positive of tumors cells. Target and citrate antigen detection methods were applied to analyze immunostainning for ETV5. Tris-EDTA antigen detection was applied for RUNX1. RT-qPCR was applied for assessment of gene expression.
Results and discussion: ETV5 was expressed only in tumors (100%) whereas RUNX1 was expressed in normal (58,3%) and tumor tissue (100%). ETV5 presented both nuclear and cytoplasmic expression, whereas RUNX1 presented only nuclear expression (although in normal tissue it was expressed in cytoplasm). However, there was no difference in ETV5 or RUNX1 expression evaluation between stages IA and IB tumors. ETV5 expression was higher in 3+ IHC positive tumors, whereas RUNX1 expression was not correlated with IHC expression.
Conclusion: There is no association between ETV5 and RUNX1 expression and myometrial invasion in early stages of endometrioid adenocarcinomas.

更多精彩内容，请点击专题报道：http://zt.cmt.com.cn/zt/igcs2012/index.html